Executive Director, Global Health Economics and Outcomes Research

Who We Are

Bio Marin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.

Since our founding in 1997, we have applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities.

Using our unparalleled expertise in genetics and molecular biology, we develop medicines for patients with significant unmet medical need. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, innovative science. With this distinctive approach to drug discovery, we’ve produced a diverse pipeline of commercial, clinical and preclinical candidates that have well-understood biology and provide an opportunity to be first-to-market or offer a substantial benefit over existing therapeutic options.

The Executive Director, Global Health Economics and Outcomes Research (HEOR), will lead the global HEOR function, with a portfolio comprising both mature, marketed products and late-stage assets in pre-launch. This role is accountable for defining and executing integrated global evidence and value strategies across the full product lifecycle, from early development through post-launch optimization.

The Executive Director HEOR reports to the SVP Global Head of Pricing, Access, Value and Evidence (PAVE) and is a member of PAVE leadership team. The position and his/her team will act as a strategic partner to Global Market Access, Medical Affairs, Clinical Development, Commercial, and Patient Advocacy teams, ensuring that payer-relevant, patient-centered evidence, and HTA submissions support successful launches, sustained reimbursement, and long-term value realization worldwide.

• Define and own the global HEOR strategy across marketed products and pipeline assets, aligned with corporate and portfolio priorities.
• Provide strategic leadership and direction to a global HEOR team, fostering scientific excellence and operational rigor.
• Manage external vendors, academic partnerships, and research collaborations to deliver high-quality evidence efficiently.

• Lead early value and evidence planning for late-stage and pre-launch assets, including development of global value stories and integrated evidence plans.
• Partner with Clinical Development to ensure trial designs, endpoints, and comparators address future HTA and payer requirements, particularly in rare diseases.
• Inform Target Product Profiles (TPPs) and access-relevant decision‑making during development.

• Support global and regional Market Access teams with HEOR inputs for launch planning, pricing strategy, and reimbursement submissions.
• Oversee development of global value dossiers, cost‑effectiveness models, budget impact analyses, and AMCP/HTA submissions.
• Anticipate and address access challenges in key markets, including evidence uncertainty common in rare and ultra‑rare indications.

• Drive post‑launch evidence generation, including real‑world evidence (RWE), registries, and long‑term outcomes studies, to support label expansions, re‑assessments, and sustained reimbursement.
• Optimize value demonstration for mature brands through updated economic models, new endpoints, and evolving payer needs.
• Monitor changes in global HTA and payer landscapes and proactively adapt evidence strategies.

• Ensure integration of patient‑reported outcomes (PROs), quality‑of‑life, caregiver burden, and disease burden data into global evidence strategies.
• Collaborate closely with Medical Affairs on publications, scientific exchange, and congress strategy.
• Partner with Patient Advocacy and external stakeholders to embed the patient voice in value narratives.

• Oversee HEOR publications, abstracts, and presentations at major…